Sex Determination and Differentiation

New England Journal of Medicine

Volumn 350, Issue 4, 2004, Pages 367-378

  MacLaughlin, David T ^a   Donahoe, Patricia K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENITAL MALFORMATION; GENITAL SYSTEM; GONAD DEVELOPMENT; HUMAN; MUTATION; NONHUMAN; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCTION; REVIEW; SEX DETERMINATION; SEX DIFFERENTIATION; SEX TRANSFORMATION; UROGENITAL SYSTEM;

ADRENAL HYPERPLASIA, CONGENITAL; FEMALE; GENES, HOMEOBOX; GERM CELLS; GONADAL DYSGENESIS; HERMAPHRODITISM; HUMANS; MALE; MULLERIAN DUCTS; MUTATION; SEX DETERMINATION (GENETICS); SEX DIFFERENTIATION; SEX DIFFERENTIATION DISORDERS;

EID: 0346502851     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra022784     Document Type: Review

References (89)

1. Donahoe PK, Crawford JD. Ambiguous genitalia in the newborn. In: Welch KJ, Randolph JG, Ravitch MM, O'Neill JA Jr, Rowe MI, eds. Pediatric surgery. 4th ed. Vol. 2. Chicago: Year Book Medical, 1986:1363-82.
2. Saitou M, Barton SC, Surani MA. A molecular programme for the specification of germ cell fate in mice. Nature 2002;418:293-300.
3. Matova N, Cooley L. Comparative aspects of animal oogenesis. Dev Biol 2001;231: 291-320.
4. Talerman A. Germ cell tumours. Ann Pathol 1985;5:145-57.
5. McLaren A, Buehr M. Development of mouse germ cells in cultures of fetal gonads. Cell Differ Dev 1990;31:185-95.
6. Matsumoto A. Spermatogenesis. Philadelphia: Lippincott-Raven, 1996:359-84.
7. Mehlmann LM, Jones TL, Jaffe LA. Meiotic arrest in the mouse follicle maintained by a Gs protein in the oocyte. Science 2002; 297:1343-5.
8. Matzuk MM, Burns KH, Viveiros MM, Eppig JJ. Intercellular communication in the mammalian ovary: oocytes carry the conversation. Science 2002;296:2178-80.
9. Prasad SV, Skinner SM, Carino C, Wang N, Cartwright J, Dunbar BS. Structure and function of the proteins of the mammalian Zona pellucida. Cells Tissues Organs 2000; 166:148-64.
10. Evans EP, Breckon G, Peters J. An XXY mouse, the result of a rearrangement between one X and a Y chromosome. Genet Res 1990;56:15-9.
11. Ma K, Sharkey A, Kirsch S, et al. Towards the molecular localisation of the AZF locus: mapping of microdeletions in azoospermic men within 14 subintervals of interval 6 of the human Y chromosome. Hum Mol Genet 1992;1:29-33.
12. Kuroda-Kawaguchi T, Skaletsky H, Brown LG, et al. The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. Nat Genet 2001;29:279-86.
13. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003;423: 825-37.
14. Dolci S, Williams DE, Ernst MK, et al. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature 1991;352:809-11.
15. Koshimizu U, Taga T, Watanabe M, et al. Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells. Development 1996;122:1235-42.
16. Labosky PA, Barlow DP, Hogan BL. Mouse embryonic germ (EG) cell lines: transmission through the germline and differences in the methylation imprint of insulin-like growth factor 2 receptor (Igf2r) gene compared with embryonic stem (ES) cell lines. Development 1994;120:3197-204.
17. Shamblott MJ, Axelman J, Wang S, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A 1998;95:13726-31. [Erratum, Proc Natl Acad Sci U S A 1999;96: 1162.]
18. Shamblott MJ, Axelman J, Wang S, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A 1998;95:13726-31. [Erratum, Proc Natl Acad Sci U S A 1999;96: 1162.]
19. McLaren A. Mammalian germ cells: birth, sex, and immortality. Cell Struct Funct 2001;26:119-22.
20. Executive summary. In: Scientific and medical aspects of human reproductive cloning. Washington, D.C.: National Academy Press, 2002.
21. Hammes A, Guo JK, Lutsch G, et al. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 2001; 106:319-29.
22. Teixeira J, Maheswaran S, Donahoe PK. Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 2001;22:657-74.
23. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995;4:351-8.
24. Miller RW, Fraumeni JF Jr, Manning MD. Association of Wilms's tumor with aniridia, hemihypertrophy and other congenital malformations. N Engl J Med 1964;270:922-7.
25. Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989;44:711-9.
26. Parker KL, Schedl A, Schimmer BP. Gene interactions in gonadal development. Annu Rev Physiol 1999;61:417-33.
27. Shen WH, Moore CC, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates the Mullerian inhibiting substance gene: a link to the sex determination cascade. Cell 1994;77:651-61.
28. Arango NA, Lovell-Badge R, Behringer RR. Targeted mutagenesis of the endogenous mouse MIS gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 1999;99:409-19.
29. Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK. Endogenous expression of Mullerian inhibiting substance in early postnatal rat Sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. Proc Natl Acad Sci U S A 2000; 97:1624-9.
30. Parker KL, Schimmer BP. Transcriptional regulation of the genes encoding the cytochrome P-450 steroid hydroxylases. Vitam Horm 1995;51:339-70.
31. Leers-Sucheta S, Morohashi K, Mason JI, Melner MH. Synergistic activation of the human type II 3beta-hydroxysteroid dehydrogenase/ delta5-delta4 isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester. J Biol Chem 1997;272:7960-7.
32. Lala DS, Rice DA, Parker KL. Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol Endocrinol 1992;6:1249-58.
33. Achermann JC, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999;22:125-6.
34. Taketo M, Parker KL, Howard TA, et al. Homologs of Drosophila fushi-tarazu factor 1 map to mouse chromosome 2 and human chromosome 9q33. Genomics 1995; 25:565-7.
35. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998; 93:445-54.
36. Parker KL, Schimmer BP, Schedl A. Genes essential for early events in gonadal development. Cell Mol Life Sci 1999;55: 831-8.
37. Ito M, Yu R, Jameson JL. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita. Mol Cell Biol 1997; 17:1476-83.
38. Crawford PA, Dorn C, Sadovsky Y, Milbrandt J. Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1. Mol Cell Biol 1998;18: 2949-56.
39. Zazopoulos E, Lalli E, Stocco DM, Sassone-Corsi P. DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis. Nature 1997;390:311-5.
40. Donahoe PK, Crawford JD, Hendren WH. Mixed gonadal dysgenesis, pathogenesis, and management. J Pediatr Surg 1979; 14:287-300.
41. Robboy SJ, Miller T, Donahoe PK, et al. Dysgenesis of testicular and streak gonads in the syndrome of mixed gonadal dysgenesis: perspective derived from a clinicopathologic analysis of twenty-one cases. Hum Pathol 1982;13:700-16.
42. Telvi L, Lebbar A, Del Pino O, Barbet JP, Chaussain JL. 45,X/46,XY mosaicism: report of 27 cases. Pediatrics 1999;104:304-8.
43. Mroz K, Carrel L, Hunt PA. Germ cell development in the XXY mouse: evidence that X chromosome reactivation is independent of sexual differentiation. Dev Biol 1999; 207:229-38.
44. Koopman P, Munsterberg A, Capel B, Vivian N, Lovell-Badge R. Expression of a candidate sex-determining gene during mouse testis differentiation. Nature 1990; 348:450-2.
45. McElreavy K, Vilain E, Abbas N, et al. XY sex reversal associated with a deletion 5′ to the SRY "HMG box" in the testis-determining region. Proc Natl Acad Sci U S A 1992; 89:11016-20.
46. Wagner T, Wirth J, Meyer J, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell 1994;79: 1111-20.
47. Ottolenghi C, Veitia R, Quintana-Murci L, et al. The region on 9p associated with 46,XY sex reversal contains several transcripts expressed in the urogenital system and a novel doublesex-related domain. Genomics 2000;64:170-8.
48. De Santa Barbara P, Bonneaud N, Boizet B, et al. Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Mullerian hormone gene. Mol Cell Biol 1998;18:6653-65.
49. Donahoe PK, Crawford JD, Hendren WH. True hermaphroditism: a clinical description and a proposed function for the long arm of the Y chromosome. J Pediatr Surg 1978;13:293-301.
50. Nihoul-Fekete C, Lortat-Jacob S, Cachin O, Josso N. Preservation of gonadal function in true hermaphroditism. J Pediatr Surg 1984;19:50-5.
51. Berkovitz GD, Fechner PY, Marcantonio SM, et al. The role of the sex-determining region of the Y chromosome (SRY) in the etiology of 46,XX true hermaphroditism. Hum Genet 1992;88:411-6.
52. Torres M, Gomez-Pardo E, Dressler GR, Gruss P. Pax-2 controls multiple steps of urogenital development. Development 1995; 121:4057-65.
53. Sanyanusin P, McNoe LA, Sullivan MJ, Weaver RG, Eccles MR. Mutation of PAX2 in two siblings with renal-coloboma syndrome. Hum Mol Genet 1995;4:2183-4.
54. Donahoe PK, Hendren WH. Pelvic kidney in infants and children: experience with 16 cases. J Pediatr Surg 1980;15:486-95.
55. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994;372: 679-83.
56. Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999;397:405-9.
57. Ma L, Benson GV, Lim H, Dey SK, Maas RL. Abdominal B (AbdB) Hoxa genes: regulation in adult uterus by estrogen and progesterone and repression in mullerian duct by the synthetic estrogen diethylstilbestrol (DES). Dev Biol 1998;197:141-54.
58. Goodman FR, Scambler PJ. Human HOX gene mutations. Clin Genet 2001;59:1-11.
59. de Santa Barbara P, Roberts DJ. Tail gut endoderm and gut/genitourinary/tail development: a new tissue-specific role for Hoxa13. Development 2002;129:551-61.
60. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.
61. Miller C, Degenhardt K, Sassoon DA. Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat Genet 1998;20:228-30.
62. Belville C, Josso N, Picard JY. Persistence of Mullerian derivatives in males. Am J Med Genet 1999;89:218-23.
63. MacLaughlin DT, Teixeira J, Donahoe PK. Reproductive tract development - new discoveries and future directions. Endocrinology 2001;142:2167-72.
64. Haqq CM, Donahoe PK. Regulation of sexual dimorphism in mammals. Physiol Rev 1998;78:1-33.
65. Cohen-Haguenauer O, Picard JY, Mattei MG, et al. Mapping of the gene for anti-Mullerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987; 44:2-6.
66. Visser JA, McLuskey A, van Beers T, et al. Structure and chromosomal localization of the human anti-mullerian hormone type II receptor gene. Biochem Biophys Res Commun 1995;215:1029-36.
67. Hutson JM, Chow DW, Ng WD. Persistent Mullerian duct syndrome with transverse testicular ectopia. Pediatr Surg Int 1987;2: 191-4.
68. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988;240:327-30.
69. Trapman J, Klaassen P, Kuiper GG, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988;153:241-8.
70. Stocco DM. Tracking the role of a star in the sky of the new millennium. Mol Endocrinol 2001;15:1245-54.
71. Di Cerbo A, Biason-Lauber A, Savino M, et al. Combined 17alpha-hydroxylase/ 17,20-lyase deficiency caused by Phe93Cys mutation in the CYP17 gene. J Clin Endocrinol Metab 2002;87:898-905.
72. Morissette J, Rheaume E, Leblanc JF, Luu-The V, Labrie F, Simard J. Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus. Cytogenet Cell Genet 1995;69:59-62.
73. Peltoketo H, Luu-The V, Simard J, Adamski J. 17Beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family: nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 1999;23:1-11.
74. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159-61.
75. Jenkins EP, Hsieh CL, Milatovich A, et al. Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991;11:1102-12.
76. Donahoe PK, Crawford JD, Hendren WH. Management of neonates and children with male pseudohermaphroditism. J. Pediatr Surg 1977;12:1045-57.
77. Lee MM, Donahoe PK, Silverman BL, et al. Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997;336:1480-6.
78. Lee MM, Donahoe PK, Hasegawa T, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571-6.
79. Rey R, Mebarki F, Forest MG, et al. Anti-Mullerian hormone in children with androgen insensitivity. J Clin Endocrinol Metab 1994;79:960-4.
80. Imperato-McGinley J, Zhu YS. Androgens and male physiology: the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002;198:51-9.
81. Speiser PW. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab Clin North Am 2001;30: 31-59.
82. Pucholt V, Fitzsimmons JS, Gelsthorpe K, Reynolds MA, Milner RD. Location of the gene for 21-hydroxylase deficiency. J Med Genet 1980;17:447-52.
83. White PC, New MI, Dupont B. Molecular cloning of steroid 21-hydroxylase. Ann N Y Acad Sci 1985;458:277-87.
84. Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference: future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002;136:320-34.
85. Chua SC, Szabo P, Vitek A, Grzeschik KH, John M, White PC. Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11). Proc Natl Acad Sci U S A 1987; 84:7193-7.
86. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989;264:20961-7.
87. New ML. Prenatal treatment of congenital adrenal hyperplasia: author differs with technical report. Pediatrics 2001;107:804. [Erratum, Pediatrics 2001;107:1450.]
88. New ML. Prenatal treatment of congenital adrenal hyperplasia: author differs with technical report. Pediatrics 2001;107:804. [Erratum, Pediatrics 2001;107:1450.]
89. Schnitzer JJ, Donahoe PK. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30: 137-54.